Literature DB >> 12761463

Induction of oral tolerance as treatment or prevention of chronic diseases associated with Chlamydia pneumoniae infection--hypothesis.

Oswald Moling1, Peter Mian.   

Abstract

BACKGROUND: Chlamydia pneumoniae infection is associated with chronic diseases such as asthma, reactive arthritis, and atherosclerosis. Several investigations and experimental results indicate an excessive immune response to heat shock protein (hsp) 60 as a possible common pathogenetic link between Chlamydia pneumoniae infection and the associated chronic diseases. CASE REPORT: A 46-year old woman with persistent C. pneumoniae infection and Reiter's syndrome had been treated for three years with antibiotics and nonsteroidal anti-inflammatory drugs without success. However, she was repeatedly free of complaints for several months following two-week cycles taking oral dilutions of Chlamydia trachomatis daily.
CONCLUSIONS: The placebo effect does not seem sufficient to explain the clinical benefits obtained repeatedly by drinking dilutions of C. trachomatis. Induction of oral tolerance (immune modulation) to hsp60 may have occurred, leading to the clinical benefits. The known risk factors for atherosclerosis do not account for all cases of atherosclerosis. If autoimmunity to hsp60 is involved in the pathogenesis of atherosclerosis, so natural acquisition of oral tolerance to hsp60 may contribute to the geographical differences in atherosclerosis prevalence.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12761463

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


  1 in total

1.  Increased IL-17, a Pathogenic Link between Hepatosplenic Schistosomiasis and Amyotrophic Lateral Sclerosis: A Hypothesis.

Authors:  Oswald Moling; Alfonsina Di Summa; Loredana Capone; Josef Stuefer; Andrea Piccin; Alessandra Porzia; Antonella Capozzi; Maurizio Sorice; Raffaella Binazzi; Lathá Gandini; Giovanni Rimenti; Peter Mian
Journal:  Case Reports Immunol       Date:  2014-07-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.